EA200700656A1 - STABLE LIQUID PLASMID DNA COMPOSITIONS - Google Patents

STABLE LIQUID PLASMID DNA COMPOSITIONS

Info

Publication number
EA200700656A1
EA200700656A1 EA200700656A EA200700656A EA200700656A1 EA 200700656 A1 EA200700656 A1 EA 200700656A1 EA 200700656 A EA200700656 A EA 200700656A EA 200700656 A EA200700656 A EA 200700656A EA 200700656 A1 EA200700656 A1 EA 200700656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
plasmid dna
plasmid
dna
stable liquid
relates
Prior art date
Application number
EA200700656A
Other languages
Russian (ru)
Other versions
EA011554B1 (en
Inventor
Франсис БЛАНШ
Мишель Кудер
Николя Мастрали
Тьерри Гиллемэн
Давид Гайак
Original Assignee
Сентелион
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Сентелион filed Critical Сентелион
Publication of EA200700656A1 publication Critical patent/EA200700656A1/en
Publication of EA011554B1 publication Critical patent/EA011554B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение относится к стабильным жидким препаратам плазмидной ДНК, которая остается не деградированной от +4°С до комнатной температуры в течение длительных периодов времени, и, таким образом, они приемлемы для хранения плазмидной ДНК, применяемой для исследований, основанной на плазмидах терапии, как, например, ДНК-вакцина и средства генной терапии. Настоящее изобретение также относится к способу хранения плазмидной ДНК в стабильной форме во времени от +4°С до комнатной температуры. Настоящее изобретение также относится к жидким композициям стабильной плазмидной ДНК для применения в способе лечения человеческого организма или организма животного посредством основанной на плазмидах терапии, как, например, ДНК-вакцинация или генная терапия.This invention relates to stable liquid preparations of plasmid DNA, which remains not degraded from + 4 ° C to room temperature for long periods of time, and is thus acceptable for storage of plasmid DNA used in plasmid-based research therapy. for example, DNA vaccine and gene therapy. The present invention also relates to a method of storing plasmid DNA in a stable form in time from + 4 ° C to room temperature. The present invention also relates to stable plasmid DNA liquid compositions for use in a method of treating a human or animal organism through plasmid-based therapy, such as DNA vaccination or gene therapy.

EA200700656A 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna EA011554B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (2)

Publication Number Publication Date
EA200700656A1 true EA200700656A1 (en) 2007-10-26
EA011554B1 EA011554B1 (en) 2009-04-28

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700656A EA011554B1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Country Status (14)

Country Link
EP (1) EP1791945A1 (en)
JP (1) JP2008512997A (en)
KR (1) KR20070058621A (en)
CN (1) CN101040041A (en)
AU (1) AU2005284244A1 (en)
BR (1) BRPI0515553A (en)
CA (1) CA2579340A1 (en)
EA (1) EA011554B1 (en)
IL (1) IL181753A0 (en)
MX (1) MX2007003214A (en)
NO (1) NO20071946L (en)
NZ (1) NZ553914A (en)
TN (1) TNSN07087A1 (en)
WO (1) WO2006029908A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (en) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Method for preparing pharmaceutical composition for inducing angiogenesis in tissues, pharmaceutical composition prepared by this method, and method of treating individual's tissue and/or organ ischemia
CN104032005B (en) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 A kind of preservatives of PCR order-checking intermediate product and store method
RU2723032C2 (en) * 2014-12-29 2020-06-08 Бонак Корпорейшн Composition stably containing a nucleic acid molecule
RU2612497C2 (en) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Optimized nucleotide sequence and pharmaceutical compositions based thereon with sustained vegf transgene expression
RU2628087C1 (en) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Composition with antimicrobial action for storage of dna or dna-containing preparations (versions) and its application
CN106554956A (en) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 A kind of method that industrialization prepares BCG CpG DNA
WO2019023937A1 (en) * 2017-08-01 2019-02-07 深圳华大智造科技有限公司 Highly efficient endonuclease buffer system
KR20200037867A (en) 2017-08-25 2020-04-09 조에티스 서비시즈 엘엘씨 Nucleic acid probe, method of immobilizing nucleic acid to a solid support using UV light, solid support including immobilized nucleic acid probe, and test apparatus including solid support
WO2019104198A2 (en) 2017-11-22 2019-05-31 Beckman Coulter, Inc. Diluent preparation modules and units
WO2020044201A1 (en) * 2018-08-30 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Methods of detecting nucleic acid
CN111718961B (en) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 Method for transforming bacteria by using plasmid
CN115404232A (en) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 Method for extracting plasmid DNA from bacteria
WO2023182614A1 (en) * 2022-03-24 2023-09-28 주식회사 헬릭스미스 Liquid formulation pharmaceutical composition comprising plasmid dna

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (en) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc BACTERIA LYSIS PROCESS AND DEVICE
EP1242441A4 (en) * 1999-12-17 2004-04-14 Merck & Co Inc Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef

Also Published As

Publication number Publication date
EP1791945A1 (en) 2007-06-06
TNSN07087A1 (en) 2008-06-02
CN101040041A (en) 2007-09-19
MX2007003214A (en) 2007-10-11
NO20071946L (en) 2007-05-29
CA2579340A1 (en) 2006-03-23
IL181753A0 (en) 2007-07-04
NZ553914A (en) 2009-11-27
KR20070058621A (en) 2007-06-08
AU2005284244A1 (en) 2006-03-23
WO2006029908A1 (en) 2006-03-23
BRPI0515553A (en) 2008-07-29
JP2008512997A (en) 2008-05-01
EA011554B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
EA200700656A1 (en) STABLE LIQUID PLASMID DNA COMPOSITIONS
BR0210839A (en) Recombination system, method for removing a chromosomal DNA DNA sequence from a eukaryotic cell or organism, organism, cell culture, organ, tissue, part or material of transgenic propagation, and use of an organism or cell culture , transgenic propagating organ, tissue, part or material
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
NO20044940L (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
SG10201903381TA (en) Artificial nucleic acid molecules
MX9708854A (en) Gene therapy for effector cell regulation.
BR112015005674A2 (en) hppd variants and methods of use
MX2007004841A (en) Triazoles useful as inhibitors of protein kinases.
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
MX2020010871A (en) 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy.
DE602004028029D1 (en) Rwendung
ATE527377T1 (en) CREATION OF GENE EXPRESSION PROFILES FROM FFPE SAMPLES
MX2020005235A (en) Transformed human cell and use thereof.
TW200724679A (en) Treatment of disease using an improved regulated expression system
RU2013121802A (en) PREVENTIVE OR THERAPEUTIC AGENT FOR TREATING FIBROSIS
NO20051561L (en) Nucleic acid molecules encoding human papillomavirus and their use in vaccine.
WO2019059817A9 (en) Vaccine based on fusion protein and plasmid dna
EA200700346A1 (en) BACTERIOPHAG- AND PROFAG-SPECIFIC PROTEINS IN CANCER GENETIC THERAPY
ITMI20030860A1 (en) METHOD FOR SELECTIVE INHIBITION OF THE N-MYC GENE
SE0403118D0 (en) New compounds 2
DE60140950D1 (en) NEW GENTHERAPEUTIC AGENT FOR TREATMENT G
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
DK1507863T3 (en) Plasmid stabilization in vivo
DE60002603D1 (en) PHOSPHORUS-CONTAINING DENDRIMERS AS TRANSFECTION AGENTS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU